Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
423 studies found for:    Amyloidosis
Show Display Options
RSS Create an RSS feed from your search for:
Amyloidosis
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Institutional Registry of Amyloidosis
Condition: Amyloidosis
Intervention:
2 Completed Long-term Outcomes of Patients With Primary Amyloidosis After Stem Cell Transplantation
Condition: Amyloidosis
Intervention:
3 Completed Risk-adapted Therapy for Primary Systemic (AL) Amyloidosis
Condition: Amyloidosis
Intervention: Drug: melphalan, thalidomide and dexamethasone
4 Not yet recruiting A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis
Condition: Amyloidosis
Interventions: Drug: Carfilzomib;   Drug: Thalidomide;   Drug: Dexamethasone
5 Completed Efficacy and Safety Study of KIACTA in Preventing Renal Function Decline in AA Amyloidosis
Condition: Amyloidosis
Interventions: Drug: KIACTA (eprodisate disodium);   Drug: Placebo
6 Completed Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-diagnosed Light-chain (AL)-Amyloidosis
Condition: Amyloidosis
Interventions: Drug: Lenalidomide;   Drug: Melphalan;   Drug: Dexamethasone
7 Enrolling by invitation Recurrent AA Amyloidosis After Renal Transplantation
Condition: AA Amyloidosis
Intervention:
8 Active, not recruiting Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis
Condition: Primary Amyloidosis
Intervention: Drug: NEOD001
9 Recruiting Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis
Condition: Amyloidosis
Intervention: Drug: Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4
10 Unknown  Study of Systemic Amyloidosis Presentation and Prognosis
Condition: Amyloidosis
Intervention:
11 Withdrawn Mixed Chimeric Transplantation for Primary Amyloidosis
Condition: Amyloidosis
Intervention: Procedure: autologous followed by nonmyeloablative allogeneic transplant
12 Completed A Trial for Systemic Light-chain (AL) Amyloidosis
Condition: AL Amyloidosis
Intervention: Drug: BMDex
13 Suspended Trial of HDM/SCT Versus HDM + Bortezomib/SCT in AL Amyloidosis
Condition: AL Amyloidosis
Interventions: Drug: Bortezomib;   Drug: Melphalan;   Drug: Neupogen;   Procedure: Stem Cell Collection;   Procedure: Stem cell infusion
14 Completed Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis
Condition: Amyloidosis
Interventions: Drug: Bortezomib;   Drug: dexamethasone;   Biological: filgrastim;   Procedure: autologous hematopoietic stem cell transplantation (ASCT);   Drug: Melphalan
15 Recruiting Idelalisib for Immunoglobulin M (IgM)-Associated Primary (AL) Amyloidosis
Condition: Amyloidosis
Intervention: Drug: Idelalisib
16 Completed Radioimmunoimaging of AL Amyloidosis
Condition: AL Amyloidosis
Intervention: Biological: 124I-labeled monoclonal antibody Mu 11-1F4
17 Completed A Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With Primary (AL) Amyloidosis
Condition: Primary Amyloidosis
Intervention: Drug: Lenalidomide
18 Completed Radioimmunoimaging of AL Amyloidosis
Condition: Primary Amyloidosis
Intervention: Biological: 124I-labeled monoclonal antibody Mu 11-1F4
19 Completed Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis
Condition: Amyloidosis
Interventions: Drug: cyclophosphamide;   Drug: lenalidomide;   Drug: dexamethasone
20 Unknown  Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL)
Condition: Amyloidosis
Intervention: Drug: Lenalidomide, Dexamethasone and Cyclophosphamide

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.